Thumbnail
Access Restriction
Open

Author Scheithauer, W. ♦ Schenk, T. ♦ Czejka, M.
Source PubMed Central
Content type Text
File Format PDF
Language English
Difficulty Level Medium
Subject Domain (in DDC) Technology ♦ Medicine & health
Abstract The potential for a pharmacokinetic interaction between epirubicin and the second-generation multidrug resistance modulating agent D-verapamil (DVPM) has been investigated in six patients with advanced colorectal cancer. Our results indicate that a significant interaction takes place. Enhanced distribution of epirubicin from the serum and altered disposition might, in fact, explain the increased level of myelotoxicity in this pilot as well as in other clinical phase II studies involving DVPM.
ISSN 15321827
Age Range above 22 year
Educational Use Research
Interactivity Type Expositive
Education Level UG and PG
Learning Resource Type Article
Publisher Date 1993-07-01
e-ISSN 15321827
Journal British Journal of Cancer
Volume Number 68
Issue Number 1
Starting Page 8


Source: PubMed Central